GB9827430D0 - Differential expression in primary breast cancer - Google Patents

Differential expression in primary breast cancer

Info

Publication number
GB9827430D0
GB9827430D0 GBGB9827430.1A GB9827430A GB9827430D0 GB 9827430 D0 GB9827430 D0 GB 9827430D0 GB 9827430 A GB9827430 A GB 9827430A GB 9827430 D0 GB9827430 D0 GB 9827430D0
Authority
GB
United Kingdom
Prior art keywords
breast cancer
differential expression
primary breast
primary
differential
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9827430.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Original Assignee
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research Ltd
Priority to GBGB9827430.1A priority Critical patent/GB9827430D0/en
Publication of GB9827430D0 publication Critical patent/GB9827430D0/en
Priority to EP99959579A priority patent/EP1137944A2/en
Priority to PCT/GB1999/004183 priority patent/WO2000036420A2/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
GBGB9827430.1A 1998-12-11 1998-12-11 Differential expression in primary breast cancer Ceased GB9827430D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB9827430.1A GB9827430D0 (en) 1998-12-11 1998-12-11 Differential expression in primary breast cancer
EP99959579A EP1137944A2 (en) 1998-12-11 1999-12-10 Differential expression in primary breast cancer
PCT/GB1999/004183 WO2000036420A2 (en) 1998-12-11 1999-12-10 Differential expression in primary breast cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9827430.1A GB9827430D0 (en) 1998-12-11 1998-12-11 Differential expression in primary breast cancer

Publications (1)

Publication Number Publication Date
GB9827430D0 true GB9827430D0 (en) 1999-02-03

Family

ID=10844141

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9827430.1A Ceased GB9827430D0 (en) 1998-12-11 1998-12-11 Differential expression in primary breast cancer

Country Status (3)

Country Link
EP (1) EP1137944A2 (en)
GB (1) GB9827430D0 (en)
WO (1) WO2000036420A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA010352B1 (en) * 2006-10-09 2008-08-29 Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) Method for differential analysis of proteoms
CN116474108A (en) 2016-12-14 2023-07-25 普渡研究基金会 Fibroblast Activation Protein (FAP) -targeted imaging and therapy
CN107988160A (en) * 2018-01-11 2018-05-04 武汉大学深圳研究院 Human breast cancer cell and its primary it is separately cultured and secondary culture method and purposes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2782292A (en) * 1991-09-18 1993-04-27 Sloan-Kettering Institute For Cancer Research Activated stromal fibroblast-specific antibody, f19 and methods of using the same
DE4228389C2 (en) * 1992-08-26 1994-07-21 Kuebler Gmbh Dr Collection and cultivation of transformed cells
US5543297A (en) * 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
EP0696352B1 (en) * 1993-04-26 2001-12-12 Coulter Corporation Method of analyzing tumor cell dna content through tumor cell enrichment
CA2247246A1 (en) * 1996-02-16 1997-08-21 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease
AU2452197A (en) * 1996-04-10 1997-10-29 California Pacific Medical Center Genes amplified in cancer cells
WO1998033915A1 (en) * 1997-02-03 1998-08-06 Human Genome Sciences, Inc. Breast cancer specific gene 1
GB9722320D0 (en) * 1997-10-22 1997-12-17 Janssen Pharmaceutica Nv Human cell cycle checkpoint proteins

Also Published As

Publication number Publication date
WO2000036420A2 (en) 2000-06-22
EP1137944A2 (en) 2001-10-04
WO2000036420A3 (en) 2000-10-19

Similar Documents

Publication Publication Date Title
AU2002212527A1 (en) Thermometry-based breast cancer risk assessment
HUP0104857A3 (en) New cancer treatments
IL122026A0 (en) Improvements in or relating to the prophylaxis of breast cancer
AU2890199A (en) Gata-3-expression in human breast carcinoma
AU2948199A (en) Breast cancer antigen
IL136167A0 (en) Conjugates useful in the treatment of prostate cancer
GB9827430D0 (en) Differential expression in primary breast cancer
GB2357434B (en) Breast shield
AU2342299A (en) Compositions and methods for detecting and treating breast cancer
GB9803447D0 (en) Cancer diagnosis
IL145048A0 (en) Casb619 involved in colon cancers
GB9613629D0 (en) Reg gene expression in cancer tissue
GB9804361D0 (en) Cancer treatment
GB9903035D0 (en) Treating cancer
IL151662A0 (en) Atm mutations in breast cancer
GB9804050D0 (en) Cancer
GB2334579B (en) Treating cancer
GB9802420D0 (en) Skin cancer alleviator
TW404173U (en) Improving type brassiere
GB9812316D0 (en) Cancer vaccines
GB9820000D0 (en) Cancer treatment
GB9818023D0 (en) Cancer treatment
GB9815855D0 (en) Conjugates useful in the treatment of prostate cancer
SI1165537T1 (en) Hydroxymatairesinol in cancer prevention
AU6282499A (en) Renal cancer associated antigens and uses therefor

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)